In8bio Inc (INAB) - Net Assets
Based on the latest financial reports, In8bio Inc (INAB) has net assets worth $22.78 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.27 Million) and total liabilities ($3.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore In8bio Inc assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.78 Million |
| % of Total Assets | 86.74% |
| Annual Growth Rate | 28.95% |
| 5-Year Change | -27.83% |
| 10-Year Change | N/A |
| Growth Volatility | 76.26 |
In8bio Inc - Net Assets Trend (2018–2025)
This chart illustrates how In8bio Inc's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of In8bio Inc to evaluate the tangible quality of the company's equity base.
Annual Net Assets for In8bio Inc (2018–2025)
The table below shows the annual net assets of In8bio Inc from 2018 to 2025. For live valuation and market cap data, see market value of In8bio Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.56 Million | +90.34% |
| 2024-12-31 | $14.48 Million | -41.94% |
| 2023-12-31 | $24.94 Million | +9.70% |
| 2022-12-31 | $22.73 Million | -40.47% |
| 2021-12-31 | $38.18 Million | +108.41% |
| 2020-12-31 | $18.32 Million | +5395.09% |
| 2019-12-31 | $-346.00K | -107.45% |
| 2018-12-31 | $4.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to In8bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13674900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.04% |
| Other Components | $168.64 Million | 611.96% |
| Total Equity | $27.56 Million | 100.00% |
In8bio Inc Competitors by Market Cap
The table below lists competitors of In8bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Exicure Inc
NASDAQ:XCUR
|
$10.20 Million |
|
Rigsave S.P.A.
XETRA:H68
|
$10.21 Million |
|
GULLBERG+JANSSON AB
F:9D7
|
$10.22 Million |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
$10.22 Million |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
$10.18 Million |
|
REC Silicon ASA
OL:RECSI
|
$10.18 Million |
|
Reliance Home Finance Limited
NSE:RHFL
|
$10.18 Million |
|
SaveLend Group AB
ST:YIELD
|
$10.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in In8bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,478,000 to 27,558,000, a change of 13,080,000 (90.3%).
- Net loss of 19,440,000 reduced equity.
- New share issuances of 27,067,000 increased equity.
- Other factors increased equity by 5,453,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.44 Million | -70.54% |
| Share Issuances | $27.07 Million | +98.22% |
| Other Changes | $5.45 Million | +19.79% |
| Total Change | $- | 90.34% |
Book Value vs Market Value Analysis
This analysis compares In8bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.31x to 0.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.24 | $1.04 | x |
| 2019-12-31 | $-0.02 | $1.04 | x |
| 2020-12-31 | $0.95 | $1.04 | x |
| 2021-12-31 | $2.03 | $1.04 | x |
| 2022-12-31 | $1.08 | $1.04 | x |
| 2023-12-31 | $0.83 | $1.04 | x |
| 2024-12-31 | $0.27 | $1.04 | x |
| 2025-12-31 | $6.30 | $1.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently In8bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -70.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-70.54%) is above the historical average (-81.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -44.78% | 0.00% | 0.00x | 1.27x | $-2.55 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.10 Million |
| 2020 | -46.71% | 0.00% | 0.00x | 1.14x | $-10.39 Million |
| 2021 | -38.38% | 0.00% | 0.00x | 1.11x | $-18.47 Million |
| 2022 | -120.61% | 0.00% | 0.00x | 1.45x | $-29.69 Million |
| 2023 | -120.33% | 0.00% | 0.00x | 1.35x | $-32.50 Million |
| 2024 | -210.23% | 0.00% | 0.00x | 1.45x | $-31.88 Million |
| 2025 | -70.54% | 0.00% | 0.00x | 1.17x | $-22.20 Million |
Industry Comparison
This section compares In8bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| In8bio Inc (INAB) | $22.78 Million | -44.78% | 0.15x | $10.19 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more